KLOW Blend: GHK-Cu, TB-500, BPC-157 and KPV Combined Research Overview

September 28, 2026 · By My Store 3 Admin

The KLOW Blend is a multi-compound research formulation containing four distinct peptide research compounds in a single lyophilised vial: GHK-Cu (copper peptide, 50mg), TB-500 (Thymosin Beta-4 analogue, 10mg), BPC-157 (pentadecapeptide, 10mg), and KPV (tripeptide, 10mg). This blend extends the three-compound GLOW Blend formulation with the addition of KPV, a tripeptide with proposed anti-inflammatory and gut-protective properties.

All Bloom Vitality products are supplied strictly for in vitro laboratory and research use only.

Individual Compound Overviews

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex, 50mg)

GHK-Cu is a naturally occurring tripeptide-copper complex studied across dermal biology, wound healing, and longevity research. Proposed mechanisms include collagen and ECM synthesis stimulation in fibroblast cultures, antioxidant enzyme upregulation, angiogenesis, and broad gene expression modulation in repair and remodelling pathways. For a full overview, see: What is GHK-Cu? Copper Peptide Research Guide.

TB-500 (Thymosin Beta-4 Analogue, 10mg)

TB-500 is a synthetic analogue of Thymosin Beta-4. Proposed mechanisms include G-actin sequestration, NF-κB-mediated anti-inflammatory signalling, and VEGF-pathway angiogenesis. Preclinical evidence is strongest in muscle, cardiac, and wound healing models. For a full overview, see: TB-500 (Thymosin Beta-4): Research Overview.

BPC-157 (Body Protection Compound-157, 10mg)

BPC-157 is a 15-amino acid synthetic peptide derived from a gastroprotective protein. Proposed mechanisms include VEGFR2 upregulation, nitric oxide system modulation, and growth hormone receptor interaction. Preclinical evidence is strongest in tendon-to-bone healing, GI mucosal repair, and bone models. For a full overview, see: What is BPC-157? Research Overview & Mechanism.

KPV (Lys-Pro-Val, 10mg)

KPV is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH). It is the shortest fragment of α-MSH proposed to retain anti-inflammatory activity and represents a distinct mechanistic component in this blend. Proposed mechanisms include:

Melanocortin receptor interaction — KPV is proposed to act at melanocortin receptor subtypes (particularly MC1R and MC3R), which mediate α-MSH’s anti-inflammatory signalling
NF-κB inhibition — KPV has been investigated for its ability to reduce NF-κB-mediated inflammatory gene expression in colonic epithelial cells, with potential relevance to intestinal inflammation research
Intestinal epithelial permeability — some in vitro and animal studies have investigated KPV’s effects on tight junction integrity in gut epithelial cell models
Anti-microbial properties — as an α-MSH fragment, KPV has been investigated for antimicrobial activity in some research contexts

Preclinical KPV research has focused primarily on intestinal inflammation and wound healing models. The most-cited in vitro work investigated KPV’s effects on cytokine secretion and NF-κB activation in intestinal epithelial cell lines treated with inflammatory stimuli.

Proposed Rationale for Combination

Compound	Primary proposed mechanism	Strongest preclinical evidence area
GHK-Cu	ECM remodelling, antioxidant gene expression	Dermal fibroblasts, wound healing
TB-500	Actin regulation, NF-κB modulation, cell migration	Muscle, cardiac, wound healing
BPC-157	VEGFR2, nitric oxide, GH receptor	Tendon-to-bone, GI, bone
KPV	Melanocortin receptor, NF-κB inhibition	Intestinal inflammation, wound healing

The KLOW Blend incorporates KPV’s proposed anti-inflammatory properties (particularly its NF-κB pathway activity) alongside the pro-healing and angiogenic mechanisms of the three GLOW Blend components. The combination is motivated by research interest in investigating whether KPV’s distinct inflammatory signalling pathway produces complementary effects in tissue repair and mucosal research models.

KLOW vs GLOW Blend

The KLOW Blend differs from the GLOW Blend solely by the addition of KPV 10mg. Researchers for whom KPV’s proposed intestinal or anti-inflammatory mechanisms are relevant to their protocol may prefer the KLOW formulation; those investigating primarily tissue repair or dermal endpoints may find the GLOW Blend adequate. For a detailed comparison of the three shared compounds, see: GLOW Blend: GHK-Cu, TB-500 and BPC-157 Combined Research Overview.

Notes on Combined Research

Attribution — multi-compound blends make mechanistic attribution of observed effects to individual components challenging. Single-compound experiments with appropriate controls are necessary to establish mechanism-specific conclusions.
Interaction effects — potential additive, synergistic, or antagonistic interactions between all four components are not characterised in published literature.
Concentration ratios — the fixed ratio (GHK-Cu 50mg : TB-500 10mg : BPC-157 10mg : KPV 10mg) reflects individual compound mass requirements. Researchers requiring different ratios should order individual compounds separately.

Research Material

Bloom Vitality supplies the KLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg) as a lyophilised research formulation, independently third-party tested for purity and potency. All components are part of our broader research peptides UK catalogue. Individual compounds are also available separately. Batch-specific Certificates of Analysis are available via our Certificates & Documentation page and Testing & Quality page.